Peroxisome proliferator-activated therapy

The activation of the retinoid X receptor, which dimerizes with peroxisome proliferator-activated receptors (PPARs), leads to an enhanced clearance of A(f from the brain of a transgenic mouse model of AD, with increased expression of ApoE and its main transporters. Both a PPARy agonist (ciplitazone) and a PPARa agonist (WT 14.643) are able to protect neurons by modulating mitochondrial fusion and fission, leading to a better response of neurons to oxidative stress, suggesting that a PPAR-based therapy could act simultaneously in different cellular components [437]. 

Etgen, G.J., Oldham, B.A., Johnson, W.T. et al. (2002) A tailored therapy for the metabolic syndrome the dual peroxisome proliferator-activate receptor-a/y agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in predinical models. Diabetes, 51, 1083-1087. 

---